SCHEMBL2980187

SCHEMBL2980187

Cc1ccc(C(=O)NCc2ccc(Cl)c(Cl)c2)cc1N

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.62
EPHX2 P34913 1/20 0.59
HDAC4 P56524 1/20 0.58
HDAC1 Q13547 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HDAC11 Q96DB2 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
HDAC9 Q9UKV0 1/20 0.58
HDAC5 Q9UQL6 1/20 0.58
HPGD P15428 1/20 0.56
MAOB P27338 1/20 0.54
TSHR P16473 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.52
NR1H4 Q96RI1 1/20 0.52
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
KMT2A Q03164 1/20 0.50
CCR2 P41597 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10322934 0.86 MEN1 (0.58) EPHX2HDAC4HDAC1HDAC7HDAC11
SCHEMBL8108036 0.84 EPHX2 (0.79) LMNAEPHX2HDAC4HDAC1HDAC7
SCHEMBL30829093 0.84 LMNA (0.58) LMNAEPHX2HDAC4HDAC1HDAC7
SCHEMBL10318179 0.83 NPC1 (0.55) LMNAHDAC1HPGDMEN1ALDH1A1
SCHEMBL7616443 0.82 LMNA (0.65) LMNAEPHX2HDAC4HDAC1HDAC7
SCHEMBL10319381 0.81 ALDH1A1 (0.70) LMNAHDAC1HDAC8HDAC6HPGD
SCHEMBL2978838 0.80 LMNA (0.65) LMNAEPHX2HDAC4HDAC1HDAC7
SCHEMBL30829111 0.80 LMNA (0.57) LMNAEPHX2HDAC4HDAC1HDAC7
SCHEMBL26188116 0.80 EPHX2 (0.61) LMNAEPHX2HDAC4HDAC1HDAC7
SCHEMBL13026611 0.79 LMNA (0.65) LMNAEPHX2HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772432-B2 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA AB (SE) 2010-08-10 US disclosed
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA 2005-02-17 US disclosed
US-6821965-B1 IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION ASTERZENECA AB (SE) 2004-11-23 US disclosed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors IL6, IL6ST, IL2 LMNA 2665/4885EPHX2 505/4885HDAC4 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.